Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Solvay Pharmaceuticals Inc and CV Therapeutics Inc have been notified by the FDA that their supplemental new drug application seeking an expansion to the label of hypertension treatment Aceon will receive a priority review, pending FDA filing of the application.
Subscribe to our email newsletter
The proposed label expansion for Aceon (perindopril erbumine,)an angiotensin converting enzyme (ACE) inhibitor with tissue activity approved in the US for the treatment of patients with essential hypertension, is based on the EUROPA (European trial on reduction of cardiac events with perindopril in patients with stable coronary artery disease) study.
This study assessed the ability of perindopril to reduce cardiovascular mortality, nonfatal myocardial infarction and cardiac arrest in a broad population of patients with stable coronary artery disease, but without heart failure or substantial hypertension.
Solvay Pharmaceuticals holds the new drug application for Aceon and submitted the supplemental new drug application (sNDA) to the FDA on December 10, 2004.